Guardian Pharmacy Services, Inc. cash flow statement GRDN

In fiscal 2025, which ended Dec 31, 2025, Guardian Pharmacy Services, Inc. generated $100.3 million of cash from operations. It spent $13.4 million on capital expenditures. That left free cash flow of $86.8 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line
FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
Operating
Depreciation and amortization
23
22
Stock-based compensation
9
14
Operating cash flow
114
100
Investing
Capital expenditures
—
13
Investing cash flow
-25
-32
Financing
Financing cash flow
-6
-7
Change in cash
Net change in cash
83
61
Free cash flow
—
87
Ratios
Free cash flow margin
—
5.99%
Capital expenditures to revenue
—
0.93%
Stock-based compensation to revenue
0.59%
0.96%
Cash conversion
1.53x
2.04x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Retail-Drug Stores and Proprietary Stores (SIC 5912)
Listed as
GRDN (NYSE)
Fiscal year ends
December 31
Incorporated in
GA
Headquarters
Atlanta, GA
SEC filer status
Accelerated filer
SEC CIK
1802255
Former names
Guardian Pharmacy Services, Inc. (until Sep 28, 2026); Guardian Pharmacy, LLC (until Jul 23, 2021)

Other Retail-Drug Stores and Proprietary Stores companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.